Scientists have published the first analysis of how four types of COVID-19 vaccines prepare the body to fight SARS-CoV-2. Their in-depth look at how T cells, B cells, antibody levels shift in the six months following vaccination is critical for understanding of how to protect people in the ongoing pandemic.
The new investigation, published in Cell, is the first study in history to compare how three different vaccine platforms trigger an immune response against the same pathogen.
“This study is important because it lets us answer how different vaccine platforms perform in terms of inducing immune responses,” says the senior author.
The researchers studied human immune responses to an mRNA platform (Pfizer-BioNTech and Moderna vaccines), a recombinant protein-based adjuvanted vaccine platform (Novavax), and a viral vector-based platform (Janssen/J&J). All four vaccines in this study were designed to prepare the immune system to fight the same target, called the SARS-CoV-2 Spike protein.
“We aren’t giving a vaccine scorecard,” says the study co-lead. “This kind of side-by-side analysis has never been done before with people who received different vaccines at the same time—in a real life setting. Just understanding the immune responses to these vaccines will help us integrate what is successful into vaccine designs going forward.”
Key findings:
-
Antibodies: After six months, those given Moderna had highest levels of neutralizing antibodies, followed by those given the Pfizer-BioNTech and Novavax vaccines. The Janssen/J&J vaccine led to the lowest neutralizing antibody levels.
-
B cells: Participants given the Janssen/J&J vaccine had the highest percentage of memory B cells after six months.
-
CD4+ T cells: All participants retained a similar percentage of memory CD4+ “helper” T cells against the virus.
-
CD8+ T cells: The Novavax vaccine led to the lowest levels of CD8+ “killer” T cells. A higher CD8+ response was seen in those given Pfizer-BioNTech, Moderna, or Janssen/J&J vaccines. Overall, after six months, only 60 to 70 percent of participants retained memory CD8+ T cells.
“This is a very valuable, comprehensive immunological evaluation of these four different vaccines,” says the author.
The new study confirms that most people retain some immune response to SARS-CoV-2, regardless of which vaccine they receive. The researchers caution that this immune memory may not prevent infection, but it appears to help fight severe disease.
“Even if it is difficult to maintain a high level of neutralizing antibodies long term, the presence of a stable cellular immunity shows that the immune system can be reactivated very quickly, in a matter of days, if there is an infection,” says the author.
Going forward, the researchers are interested in the effects of COVID-19 vaccine booster shots on long-term immune memory. The scientists are also keeping a close eye on immune cell responses to SARS-CoV-2 variants and are currently analyzing immune responses in people who were vaccinated and experienced “breakthrough” infections.
https://www.cell.com/cell/fulltext/S0092-8674(22)00653-5
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Fhumoral-and-cellular&filter=22
Latest News
Citrullination is a key pla…
By newseditor
Posted 14 Sep
Senolytic therapy clinical…
By newseditor
Posted 14 Sep
Genetic tools probe microbi…
By newseditor
Posted 13 Sep
A secret passage for mutant…
By newseditor
Posted 11 Sep
Specialized T cells in the…
By newseditor
Posted 10 Sep
Other Top Stories
Nuclear transport protein prevents the aggregation of FUS
Read more
Green tea molecule could prevent heart attacks
Read more
A new twist in transcription!
Read more
Recombinant proteins made from human blood!
Read more
Controlling crowding inside the cell
Read more
Protocols
Genetic manipulation of Pat…
By newseditor
Posted 13 Sep
Single-nucleus RNA sequenci…
By newseditor
Posted 08 Sep
Engineering RNA export for…
By newseditor
Posted 25 Aug
ATP production from electri…
By newseditor
Posted 21 Aug
Labeling PIEZO2 activity in…
By newseditor
Posted 20 Aug
Publications
Timing of lifespan influenc…
By newseditor
Posted 16 Sep
Transformer-based biomarker…
By newseditor
Posted 16 Sep
Somatic variants of MAP3K3…
By newseditor
Posted 16 Sep
The NLRP3 inflammasome and…
By newseditor
Posted 15 Sep
Targeting the metabolism of…
By newseditor
Posted 15 Sep
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar